Every material Form 8-K DAXOR CORP has filed with the SEC since August 07, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Daxor Corporation closed a registered direct offering of 765,958 common shares at $11.75 per share on January 26, 2026, after agreeing to the deal on January 23. Net proceeds after placement agent fees and expenses were approximately $8,142,006, with Lake Street Capital Markets acting as placement agent. The sale adds new shares outstanding, which dilutes existing holders, but also adds cash to the company.
Shares issued: 765,958 at $11.75 per share under a registered direct offering
Net proceeds after placement agent fees and expenses: approximately $8,142,006
Agreement signed January 23, 2026; closing took place January 26, 2026
Shares registered under shelf registration File No. 333-281622, declared effective January 20, 2026
Daxor Corporation filed a Form 8-K on January 23, 2026, under Item 8.01 (Other Events) to attach its current investor presentation as Exhibit 99.1. The filing contains no financial results, guidance, or other figures in its text, so it gives shareholders no new quantitative information beyond the presentation itself.
Filing date: January 23, 2026; signed by Chief Financial Officer Robert J. Michel
Item 8.01 (Other Events): attaches current investor presentation as Exhibit 99.1
Filing text states no financial figures; the presentation content is not reproduced in the filing text provided
Daxor Corporation announced FDA 510(k) clearance (K251087) for its next-generation, rapid, portable lab-based Blood Volume Analyzer (BVA), according to a press release dated August 7, 2025. The filing does not include financial results or a financial impact estimate, so its effect on shareholders is not quantified.
FDA 510(k) clearance was granted under number K251087 for the new Daxor BVA device.
The company says the device provides results three times faster than its predecessor and weighs 7 lbs.
The system was developed under contract with the U.S. Department of Defense, including the U.S. Army and the Defense Health Agency.
The company states that more than 75,000 tests have shipped to date.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every DAXOR CORP filing is on SEC EDGAR ↗. 8-K briefs of other companies →